EMA starts rolling review of CureVac vaccine

12 February 2021

ema_conference-room-xl_credit_rob-acket_large

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has started a rolling review of CVnCoV, a COVID 19 vaccine being developed by German mRNA company CureVac (Nasdaq: CVAC).

This comes on the back of preliminary results from non-clinical data and early clinical studies in adults. The data suggest that the vaccine triggers the production of antibodies and immune cells that target SARS-CoV-2, the virus that causes COVID 19.

CureVac is currently conducting trials in people to assess the vaccine’s safety, immunogenicity and effectiveness against COVID-19. The EMA will evaluate data from these and other clinical trials as they become available.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK